Welcome reception

Welcome & framing the conversation
Chairs: Claire Harrison & John Mascarenhas

Part 1: Where have we been and where are we going

• The historical evolution of MPN treatment: From cytoreduction to precision medicine: TBC
• Current endpoint landscape in MPN clinical trials: TBC

Part 2: Patient-centered outcomes in MPNs: What matters most

• Talk 1: TBC
• Talk 2: TBC

Panel discussion 1: What constitutes meaningful benefit in MPNs today?
Chairs: Claire Harrison, John Mascarenhas & Ruben Mesa
Panellists: TBC

Break

Part 3: Regulatory considerations in endpoint development

• Talk title TBC: TBC

Q & A for Part 3: Regulatory considerations in endpoint development   

Part 4: Aligning scientific innovation, patient experience, and regulatory standards
Chairs: TBC & TBC

• Role of molecular endpoints: TBC
• How best to integrate symptoms and QoL beat ruxolitinib or non-inferior: TBC
• Durability of spleen response: TBC
• Anemia benefit: TBC

Panel discussion 2: Aligning scientific innovation, patient experience, and regulatory standards
Chairs: TBC & TBC
Panellists: TBC 

Working group session close and next steps
Claire Harrison & John Mascarenhas

iwMPN welcome reception

Welcome and introduction
Claire Harrison & Amer Zeidan

Session 1: Innovation
Chairs: TBC & TBC

• Are we ready to mainline AI?: TBC
• Wearable devices latest data: TBC
• Is NGS sufficient to understand the molecular landscape?: TBC
• What have we learned from LLM multimodal models in MPN?: TBC

Panel discussion

Session 2: Targeted therapies: CALR, JAK-selective and beyond
Chairs: TBC & TBC

• Latest on CALR biology: TBC
• INCA latest data: TBC
• AJAX: TBC
• INCB: TBC

Panel discussion

Break

Session 3: Frontline myelofibrosis combination strategies
Chairs: TBC & TBC

• Pelabresib: TBC
• Selinexor: TBC
• Navetamadlin: TBC
• Interferon: TBC
• What treatment for a low-risk MF in 2026: TBC

Panel discussion

Lunch

Session 4: Second-line myelofibrosis: Sequencing and positioning
Chairs: TBC & TBC

• Nuvisertib: TBC
• Imetelstat: TBC 
• T-regs: TBC
• Elritercept: TBC 
• Luspatercept: TBC 
• DISC-0974: TBC

Panel discussion

Break

Session 5: Polycythaemia vera and essential thrombocythemia: Emerging agents and targets
Chairs: TBC & TBC

• Is ruxolitinib ready for front line therapy in PV?: TBC
• Bomedemstat in ET and PV: TBC
• What is interferon resistance or intolerance?: TBC
• Where is the unmet need in ET?: TBC

Panel discussion

Session 6: Systemic mastocytosis: Rapidly evolving targeted therapy
Chairs: TBC & TBC

• Talk title TBC: TBC
• Talk title TBC: TBC
• Talk title TBC: TBC
• Talk title TBC: TBC

Panel discussion

Session 7: Summary of iwMPN working group session: Endpoints in MPN
Claire Harrison & John Mascarenhas

Day 2 conclusions & close
Claire Harrison & John Mascarenhas

iwMDS welcome reception

Welcome to Day 3
John Mascarenhas & Amer Zeidan

Keynote talk 1
BPDCN: TBC

Session 8: From CHIP to blast phase
Chairs: TBC & TBC

• Clonal evolution in MPN how often to screen, when to act and what to do: TBC 
• Accelerated blastic phase management including fit and unfit patients: TBC 

Panel discussion

Break

Session 9: CMML, MDS/MPN overlaps and VEXAS
Chairs: TBC & TBC

• Improving prognostication in CMML: TBC
• Oral HMAs for CMML: TBC
• Novel therapies for CMML: TBC
• JAK inhibitors and evolving therapies for MDS/MPN overlaps: TBC
• How I treat VEXAS: TBC

Panel discussion

Session 10: From CHIP to MDS
Chairs: TBC & TBC

• The role of NK cells in the progression from CH to MDS: TBC
• Biological insights on marrow microenvironment driving progression in CH: TBC
• What has been learned about CH from the CHIVE registry?: TBC
• How to design studies for CCUS and CHIP: TBC

Panel discussion

Lunch

Session 11: Diagnosis, classification and prognostication in MDS and MDS/MPN
Chairs: TBC & TBC

• Incorporation of flow cytometry in diagnosis and classification of MDS: TBC
• Harmonized classification for MDS: TBC
• Harmonized classification for CMML and MDS/MPN: TBC
• Prognostication in TP53-mutated MDS – is there any “good” subtype?: TBC
• How can AI help in MDS prognostication and management?: TBC

Panel discussion

Session 12: What is the best current best practice in lower risk MDS?
Chairs: TBC & TBC

• Debate: Venetoclax still has a role for venetoclax in higher-risk MDS
  • Yes: TBC
  • No: TBC
• How I will treat higher-risk MDS in 2027: TBC
• Lessons learned from a decade of higher risk MDS trials: TBC

Panel discussion

Break

Session 13: What is the role of allo-SCT for the treatment of MDS?
Chairs: TBC & TBC

• Debate: Should we transplant TP53-mutated MDS patients?
  • No: TBC 
  • Yes: TBC 
• Which MDS patients should be transplanted in the era of PTCy?: TBC 
• Does non-transplant cellular therapy have a future in MDS?: TBC 

Panel discussion

Day 3 conclusions & close 
John Mascarenhas & Amer Zeidan

Faculty dinner

Welcome to Day 4
Amer Zeidan

Session 15: What are the right endpoints for future MDS clinical trials?
Chairs: TBC & TBC 

• What are the right endpoints for lower-risk MDS trials?: TBC 
• What are the right endpoints for higher-risk MDS trials?: TBC 
• Peripheral blood CR as a new endpoint in clinical trials: TBC 
• FDA views on drug approval for MDS: TBC 
• FDA views on drug approval for CMML and MDS/MPN overlap: TBC 

Panel discussion

Session 16: How should we think about MRD in MDS?
Chairs: TBC & TBC 

• MRD in MDS – Is this even a thing?: TBC 
• Flow cytometry for MRD in MDS: TBC 
• Molecular MRD in MDS – What can we learn from longitudinal deep sequencing in higher-risk MDS?: TBC 
• A clinician’s view on challenges of MRD use in MDS: TBC 

Panel discussion

Break

Session 17: Novel targets in MDS
Chairs: TBC & TBC

• What are the next promising targets for higher-risk MDS?: TBC
• What are the next promising targets for lower-risk MDS?: TBC
• Targeting inflammation in MDS: TBC

Panel discussion

Session 18: Quo vadis MDS? Where do we go from here? Short perspectives on future plans for clinical trials from around the world (Part 1)
Chairs: TBC & TBC

• Myelomatch’s plan for drug development in MDS: TBC
• CTEP views on use for novel agents in MDS: TBC
• Important US MDS trials: TBC
• The Canadian plan for MDS trials: TBC

Panel discussion

Session 19: Quo vadis MDS? Where do we go from here? Short perspectives on future plans for clinical trials from around the world (Part 2)
Chairs: TBC & TBC

• The Chinese plan for MDS trials: TBC
• The Scandinavian plan for MDS trials: TBC
• The Greek plan for MDS trials: TBC
• The Australian plan for MDS trials: TBC

Panel discussion

Meeting summary and close
Amer Zeidan